Skip to main content
CDC Website

MMWR: Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations--United States, 2001

This report provides preliminary information about 21 cases of liver injury associated with rifampin-pyrazinamide (RIF-PZA) and the revised recommendations on selecting appropriate therapy for patients with latent TB infection and monitoring the use of RIF-PZA to treat infection.

Audiences:
Health Professionals
Author:
Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR
Focus Area:
TB
Subjects:
Treatment- Adverse Reactions
Case Management
Treatment Guidelines Materials
Treatment - Latent TB infection (Inactive TB)
Treatment- Medication Information
Publication Date:
2001
Format:
Report
3 p.: b&w; refs.
Links:
http://www.cdc.gov/mmwr/PDF/wk/mm5034.pdf
Links:
Last Updated Date:
Publication ID:
31320